Lanifibranor dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Lanifibranor is a daily pill for fatty liver disease that works on all three PPAR switches. Its 1,000-person final-stage study finished in September 2026, with results due by the end of the year.
Evidence grade for Lanifibranor: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Lanifibranor is a daily pill for fatty liver disease. It switches on three PPAR receptors that control how the liver handles fat, inflammation and scarring. It is not approved. Results from its large final-stage study are due by the end of 2026.
What people take it for
- Calming liver inflammation from fatty liver disease.
- A better response to insulin.
What studies in people showed
The mid-stage study had 247 people with active fatty liver disease and ran 24 weeks. On 1200 mg, 55 percent had less liver inflammation without worse scarring. On a dummy pill, 33 percent did. The 800 mg dose did not clearly beat the dummy. Diarrhoea, nausea, leg swelling and weight gain were more common on the drug. The maker paid for the study. A final-stage study of about 1,000 people finished in September 2026.
What people report
Reports, not study results
The good
- In the study on this page, more than half of people on the higher dose had less liver inflammation.
The bad
- Diarrhoea, nausea, leg swelling and weight gain were more common on the drug in the study on this page.
Where these come from: Both lines are from the study on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Wait for the big result, due by the end of 2026. In the meantime, get your liver numbers on your blood work.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Lanifibranor?
Lanifibranor is a daily pill for fatty liver disease that works on all three PPAR switches. Its 1,000-person final-stage study finished in September 2026, with results due by the end of the year.
Lanifibranor switches on all three PPAR receptors, called alpha, delta and gamma. These control how the liver handles fat, inflammation and scarring, and how the body uses insulin. In the mid-stage NATiV2 study, 247 people with active fatty liver disease took it or a dummy pill daily for 24 weeks. On 1200 mg, 55 percent had less liver inflammation without worse scarring, against 33 percent on the dummy. The 800 mg dose did not clearly beat the dummy. Diarrhoea, nausea, leg swelling and weight gain were more common on the drug. The large final-stage study, NATiV3, saw its last patient on September 2, 2026. First results are expected in the last quarter of 2026, with a filing in 2027 if they are good. It is the next big fatty liver result due after resmetirom was approved.
How does Lanifibranor work?
It switches on all three PPAR receptors. That improves how the liver handles fat, and it calms inflammation and the cells that lay down scar tissue.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2021 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 434.9 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Lanifibranor, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2026Inventiva announces last patient visit in NATiV3 Phase 3
The trial has finished and has published nothing yet. The last patient in the large final-stage lanifibranor study was seen on 2 September 2026, and the first summary figures were expected before the end of the year. This is the biggest liver readout due after resmetirom's approval. Until it lands, the drug rests on a mid-stage trial from 2021.
Topline expected Q4 2026.
- Study in people2021A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH (NATiV2)
The mid-stage study passed its main test, but only at the higher dose. 247 people with active fatty liver disease took lanifibranor or a dummy pill daily for 24 weeks. On 1200 mg, 55 percent had less liver inflammation without worse scarring, against 33 percent on the dummy. The 800 mg dose did not clearly beat the dummy. Diarrhoea, nausea, leg swelling and weight gain were more common on the drug. Inventiva, which makes it, paid for the study.
Met its primary endpoint at 24 weeks.
Common questions
Has Lanifibranor been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. Lanifibranor is a daily pill for fatty liver disease that works on all three PPAR switches. Its 1,000-person final-stage study finished in September 2026, with results due by the end of the year.
What is the Lanifibranor dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is Lanifibranor FDA-approved?
Investigational; a final-stage study has finished giving doses
Is lanifibranor related to pioglitazone?
Pioglitazone switches on only PPAR-gamma. Lanifibranor switches on alpha, delta and gamma. The aim is a liver benefit with less fluid build-up and weight gain.